As of November 6, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of DiaMedica Therapeutics Inc. The largest reported stake is Trill Ab's, at 16.9%. 9 filings are on record since July 30, 2025 (Schedule 13G/A, February 6, 2026).
Sell to companies like DiaMedica Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Cooperman Leon G. · Sole voting: 3,450,000 · Shared voting: 0 · Sole dispositive: 3,450,000 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-02-17
- · Reporting person: Dialectic Life Sciences SPV LLC · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-02-17
- · Reporting person: Trill Ab · Sole voting: 0 · Shared voting: 8,825,742 · Sole dispositive: 0 · Shared dispositive: 8,825,742 · SCHEDULE 13G/A, 2026-02-06
- · Reporting person: Richard Jacinto II · Sole voting: 4,958,823 · Shared voting: 0 · Sole dispositive: 4,958,823 · Shared dispositive: 0 · SCHEDULE 13G/A, 2025-11-07
- · Holder: Cooperman Leon G. · Percent: 6.3% · SCHEDULE 13G/A
DiaMedica Therapeutics Inc. has 9 Schedule 13D or 13G filings on record since 2025-07-30. 4 holders' latest filing reports 5% or more of voting common shares, no par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 16.9% | 8,825,742 | SCHEDULE 13G/A, 2026-02-06 | 2025-12-31 | |
| 16.28% | 8,383,577 | SCHEDULE 13G/A, 2025-07-30 | 2025-07-23 | |
| 9.6% | 4,958,823 | SCHEDULE 13G/A, 2025-11-07 | 2025-09-30 | |
| 6.6% | 3,450,000 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 | |
| 0.3% | 153,983 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
Holding shares or following this stake? See who's behind DiaMedica Therapeutics Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on DiaMedica Therapeutics Inc. and the records around it.
DiaMedica Therapeutics Inc. elsewhere on the record
- Form D filing Jul 2025
- Who owns it
Companies that share a holder
- Cooperman Leon G. also filed stake reports on 6 other companies: WhiteHawk Minerals Corp. (Aug 2026), Fidelis Insurance Holdings Ltd (Aug 2026), ASHLAND INC. (Aug 2026)
Watch DiaMedica Therapeutics Inc.
Get an email when DiaMedica Therapeutics Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on DiaMedica Therapeutics Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on DiaMedica Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on DiaMedica Therapeutics Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
10 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Trill Ab | 0 | 8,825,742 | 0 | 8,825,742 | SCHEDULE 13G/A, 2026-02-06 |
| Jan Stahlberg | 0 | 8,825,742 | 0 | 8,825,742 | SCHEDULE 13G/A, 2026-02-06 |
| Richard Jacinto II | 4,958,823 | 0 | 4,958,823 | 0 | SCHEDULE 13G/A, 2025-11-07 |
| Cooperman Leon G. | 3,450,000 | 0 | 3,450,000 | 0 | SCHEDULE 13G/A, 2026-02-17 |
| Dialectic Life Sciences SPV LLC | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-02-17 |
| Dialectic LS Manager LLC | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-02-17 |
| Dialectic Capital Management, LP | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-02-17 |
| Dialectic Partners, LLC | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-02-17 |
| John Fichthorn | 153,983 | 0 | 153,983 | 0 | SCHEDULE 13G/A, 2026-02-17 |
The latest filing names DiaMedica Therapeutics Inc., with its principal executive office as 301 Carlson Parkway, Suite 210, Minneapolis, MN 55305 (SCHEDULE 13G/A, 2026-02-17).
What the percentages are based on
Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of the securities of the Issuer beneficially owned by such Reporting Person as of the date of the event which requires filing of this statement and is incorporated herein by reference.Trill Ab, SCHEDULE 13G/A, 2026-02-06
9.6%, which is based on 51,688,913 Voting Common Shares of the Issuer outstanding as of August 8, 2025, as disclosed in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on August 12, 2025.Richard Jacinto II, SCHEDULE 13G/A, 2025-11-07
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-30 | TomEnterprise AB | 16.28% | SCHEDULE 13G/A |
| 2025-07-30 | Trill AB | 13.14% | SCHEDULE 13G/A |
| 2025-08-27 | Cooperman Leon G. | 6% | SCHEDULE 13G |
| 2025-09-04 | Trill AB | 15.02% | SCHEDULE 13G/A |
| 2025-10-15 | Cooperman Leon G. | 6.3% | SCHEDULE 13G/A |
| 2025-11-07 | Richard Jacinto II | 9.6% | SCHEDULE 13G/A |
| 2026-02-06 | Trill Ab | 16.9% | SCHEDULE 13G/A |
| 2026-02-17 | John Fichthorn | 0.3% | SCHEDULE 13G/A |
| 2026-02-17 | Cooperman Leon G. | 6.6% | SCHEDULE 13G/A |
Questions about who owns DiaMedica Therapeutics Inc.
Who owns DiaMedica Therapeutics Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of DiaMedica Therapeutics Inc.: Trill Ab (16.9%, Schedule 13G/A, filed 2026-02-06), TomEnterprise AB (16.28%, Schedule 13G/A, filed 2025-07-30), Richard Jacinto II (9.6%, Schedule 13G/A, filed 2025-11-07) and Cooperman Leon G. (6.6%, Schedule 13G/A, filed 2026-02-17).
Who are the largest shareholders of DiaMedica Therapeutics Inc.?
By the share each holder's latest filing reports, the largest holders of DiaMedica Therapeutics Inc. on this page are Trill Ab (16.9%), TomEnterprise AB (16.28%) and Richard Jacinto II (9.6%).
When did Trill Ab buy into DiaMedica Therapeutics Inc.?
The filings give report dates, not purchase dates. The earliest filing from Trill Ab on this page is the Schedule 13G/A, filed 2025-07-30, reporting 13.14%; its latest, Schedule 13G/A filed 2026-02-06, reports 16.9%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 9 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for DiaMedica Therapeutics Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 25, 2025 | Form D, private offering | $30.10M sold | Form D page | Source |
Tools for this story
Each opens in a new tab, filled in for DiaMedica Therapeutics Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.